AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01658228
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
Trial: NCT01658228
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
Trial: NCT02056938
Drug: Anti-Thymocyte Globulins treatment
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02056938
Drug: Basiliximab treatment
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006111
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04470141
Drug: SHC014748M treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Trial: NCT00532558
Drug: Lapaquistat acetate
RxNorm normalized name: Lapaquistat
DrugBank: Lapaquistat (DB16215)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00843856
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
Trial: NCT00622401
Drug: Interleukin-12
RxNorm normalized name: interleukin-12
DrugBank: Edodekin alfa (DB15631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously at dose of 30ng/kg
Trial: NCT00622401
Drug: Interleukin-12
RxNorm normalized name: interleukin-12
DrugBank: Edodekin alfa (DB15631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously at dose of 100ng/kg
Trial: NCT00557128
Drug: COREG CR and lisinopril (FDC)
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04400331
Drug: Valbenazine
RxNorm normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Trial: NCT00841100
Drug: Kuvan
RxNorm normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg/kg by mouth once daily
Trial: NCT03338972
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02480764
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil tablets
Trial: NCT02480764
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 80 mg capsules
Trial: NCT02480764
Drug: Azilsartan medoxomil Placebo
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil placebo-matching tablets
Trial: NCT02480764
Drug: Valsartan Placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan placebo-matching capsules
Trial: NCT01313416
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
Trial: NCT03914300
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03849651
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
Trial: NCT03849651
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1
Trial: NCT03849651
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
Trial: NCT03849651
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI
Trial: NCT04035109
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
Trial: NCT04361136
Drug: Delgocitinib cream
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cream for topical application
Trial: NCT04361136
Drug: Delgocitinib cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Trial: NCT04035109
Drug: Preservative-free 0.9% sodium chloride (Placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
Trial: NCT03929367
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV administration of oxytocin
Trial: NCT02594423
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
Trial: NCT00957580
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Trial: NCT00957580
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Trial: NCT00957580
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Trial: NCT03970772
Drug: Glucagon Injection
RxNorm normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
Trial: NCT02211859
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619879
Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2.
Trial: NCT00619879
Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2.
Trial: NCT03090087
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
Trial: NCT00957580
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Trial: NCT00957580
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Trial: NCT02230800
Drug: Tocovid SupraBio plus pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002711
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002711
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00179556
Drug: Isoflavone supplement
RxNorm normalized name: Soyrel Soy Isoflavone Supplement
DrugBank: Flavone (DB07776)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01160315
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin: intramusculAR injection every 3 months
Trial: NCT01160315
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/day per os until during chemotherapy
Trial: NCT01534962
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration, BID; for a maximum of 112 days.
Trial: NCT02795858
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02795858
Drug: Somatostatin Analog
RxNorm normalized name: Somatostatin analog
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04231331
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin 5mg qd for 12 months
Trial: NCT02902081
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00652730
Drug: Buspirone HCl
RxNorm normalized name: buspirone HCl
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 30 mg, single-dose, fasting conditions
Trial: NCT00652730
Drug: Buspirone HCl
RxNorm normalized name: buspirone HCl
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 30 mg, single-dose, fed conditions
Trial: NCT00652730
Drug: Buspar
RxNorm normalized name: BuSpar
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 30 mg, single-dose, fed conditions
Trial: NCT03026517
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03026517
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03026517
Drug: Phenformin
RxNorm normalized name: phenformin
DrugBank: Phenformin (DB00914)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03746106
Drug: Trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
Trial: NCT03746106
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
Trial: NCT01651403
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.
Trial: NCT00567489
Drug: Extraneal
RxNorm normalized name: Extraneal
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5% Icodextrin
Trial: NCT00567489
Drug: Nutrineal
RxNorm normalized name: Nutrineal PD4
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amino Acids 1.1%
Trial: NCT03083704
Drug: Apixaban 5 MG
RxNorm normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: factor Xa inhibitor
Trial: NCT03083704
Drug: Rivaroxaban 20 MG
RxNorm normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: factor Xa inhibitor
Trial: NCT01760460
Drug: Anacetrapib
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01760460
Drug: Placebo for anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01195259
Drug: allocation of treatment with metformin or rosiglitazone
RxNorm normalized name: metformin / rosiglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
Trial: NCT01041833
Drug: atRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
Trial: NCT03083704
Drug: Enoxaparin sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low molecular weight heparin
Trial: NCT03083704
Drug: Edoxaban 60 MG
RxNorm normalized name: edoxaban 60 MG
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: factor Xa inhibitor
Trial: NCT00087607
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000/1200mg/day po
Trial: NCT00087607
Drug: Peginterferon alfa-2b (PEG-Intron)
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 micrograms/kg sc weekly
Trial: NCT00087607
Drug: Peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc weekly
Trial: NCT00868608
Drug: Inotuzumab Ozogamicin (CMC-544)
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
Trial: NCT02255799
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
Trial: NCT01649622
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
Trial: NCT04025879
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04025879
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04025879
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT02616484
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.
Trial: NCT04025879
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04025879
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01136642
Drug: Nicotrol
RxNorm normalized name: Nicotrol
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02079532
Drug: rituximab [MabThera]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 g was given by intravenous infusion on Days 1 and 15
Trial: NCT01226069
Drug: Glycerine Magnesium sulphate paste
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
Trial: NCT01577680
Drug: Inhaled GSK573719/vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1